Matthew R Smith1, Maneesha Mehra2, Sandhya Nair3, Joe Lawson2, Eric J Small4. 1. Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA. Electronic address: mrsmith@mgh.harvard.edu. 2. Health Economics Design and Analytics, Janssen Research & Development, Raritan, NJ. 3. Heath Economics Design and Analytics, Janssen Research & Development, Beerse, Belgium. 4. Division of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Abstract
BACKGROUND: Metastasis-free survival (MFS) has been shown to be predictive of overall survival (OS) in hormone-sensitive localized prostate cancer. We evaluated the relationship between MFS and OS in nonmetastatic castration-resistant prostate cancer (nmCRPC). PATIENTS AND METHODS: A retrospective analysis of 1207 high-risk patients with nmCRPC from the SPARTAN study (clinicaltrials.gov, NCT01946204) was undertaken. Landmark analyses of MFS status at several time points from randomization were performed to minimize guarantee-time bias. Hazard ratio (HR) of death as a function of MFS status was estimated based on a Cox proportional hazards model with 2-sided 95% confidence interval (CI). Estimated HRs were adjusted for stratification factors. Correlation analysis was performed using the Fleischer method. RESULTS: At all time points, MFS status strongly predicted OS. At landmark time points of 6, 9, and 12 months, risk of death was significantly higher for patients with metastases versus those without (adjusted HR at 6 months = 4.12; 95% CI, 2.60-6.54; P < .0001). MFS was positively correlated with OS based on the Fleischer method (HR, 0.69; 95% CI, 0.69-0.70; P < .0001). Approximately one-half of the variability in OS can be explained by MFS. CONCLUSION: Metastasis development, regardless of time point, is associated with significantly greater risk of death in men with high-risk nmCRPC; hence, MFS is predictive of OS.
BACKGROUND: Metastasis-free survival (MFS) has been shown to be predictive of overall survival (OS) in hormone-sensitive localized prostate cancer. We evaluated the relationship between MFS and OS in nonmetastatic castration-resistant prostate cancer (nmCRPC). PATIENTS AND METHODS: A retrospective analysis of 1207 high-risk patients with nmCRPC from the SPARTAN study (clinicaltrials.gov, NCT01946204) was undertaken. Landmark analyses of MFS status at several time points from randomization were performed to minimize guarantee-time bias. Hazard ratio (HR) of death as a function of MFS status was estimated based on a Cox proportional hazards model with 2-sided 95% confidence interval (CI). Estimated HRs were adjusted for stratification factors. Correlation analysis was performed using the Fleischer method. RESULTS: At all time points, MFS status strongly predicted OS. At landmark time points of 6, 9, and 12 months, risk of death was significantly higher for patients with metastases versus those without (adjusted HR at 6 months = 4.12; 95% CI, 2.60-6.54; P < .0001). MFS was positively correlated with OS based on the Fleischer method (HR, 0.69; 95% CI, 0.69-0.70; P < .0001). Approximately one-half of the variability in OS can be explained by MFS. CONCLUSION: Metastasis development, regardless of time point, is associated with significantly greater risk of death in men with high-risk nmCRPC; hence, MFS is predictive of OS.
Authors: Sungmin Woo; Chong Hyun Suh; Andreas G Wibmer; Anton S Becker; Min Yuen Teo; Mithat Gönen; Hedvig Hricak; Howard I Scher; Michael J Morris; Hebert Alberto Vargas Journal: Clin Genitourin Cancer Date: 2021-11-15 Impact factor: 2.872
Authors: Rodolfo Borges Dos Reis; Alejandro Alías-Melgar; Andrés Martínez-Cornelio; Silvia P Neciosup; Juan Pablo Sade; Marcos Santos; Gustavo Martin Villoldo Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302
Authors: Eric Powers; Georgia Sofia Karachaliou; Chester Kao; Michael R Harrison; Christopher J Hoimes; Daniel J George; Andrew J Armstrong; Tian Zhang Journal: J Hematol Oncol Date: 2020-10-28 Impact factor: 17.388
Authors: Igor Tsaur; Isabel Heidegger; Jasmin Bektic; Mona Kafka; Roderick C N van den Bergh; Jarmo C B Hunting; Anita Thomas; Maximilian P Brandt; Thomas Höfner; Eliott Debedde; Constance Thibault; Paola Ermacora; Fabio Zattoni; Silvia Foti; Alexander Kretschmer; Guillaume Ploussard; Severin Rodler; Gunhild von Amsberg; Derya Tilki; Christian Surcel; Barak Rosenzweig; Moran Gadot; Giorgio Gandaglia; Robert Dotzauer Journal: Cancer Med Date: 2021-08-10 Impact factor: 4.452